Cellbricks’ Post

Megan Webster, PhD, Principal Scientist, presenting at The 3Rs Collaborative (3RsC) Neuromuscular & Fibrosis MPS workshop today on: 📌 'Utilisation of high-content imaging for the study of lung fibrosis.' By leveraging the ability to image multiple fluorophores at high-throughput we are able to provide insight into drug-induced changes in matrix proteins which are known to contribute to the pathophysiology of lung fibrosis, enabling high-throughput screening of anti-fibrotic therapeutics. Find out more about our Fibroblast-to-Myofibroblast Transition (FMT) Assay here: https://lnkd.in/ePdxzcZm #Lung #Fibrosis #MPS #FMT

Join Megan Webster, PhD, Principal Scientist, for a talk at The 3Rs Collaborative (3RsC) webinar tomorrow: 📌 'Utilisation of high-content imaging for the study of lung fibrosis.' By leveraging the ability to image multiple fluorophores at high-throughput we are able to provide insight into drug-induced changes in matrix proteins which are known to contribute to the pathophysiology of lung fibrosis, enabling high-throughput screening of anti-fibrotic therapeutics. Register here: https://lnkd.in/e54TGvDP #Lung #Fibrosis #MPS

Happy #FluorescenceFriday everyone! Below you can see a fluorescent microscopy image of organoid derived from pancreatic ductal adenocarcinoma (PDAC) samples, treated with standard of care chemotherapeutic, counterstained with DAPI and stained using viability dye Propidium Iodide (PI). 👉 At InnoSer, we have access to various patient-derived samples, suitable for in vitro organoid and in vivo xenograft applications for efficacy studies. Consult our PDX/O platform webpage here to learn more information about our capabilities: https://lnkd.in/e5-NNNgh 👉 Considering using patient-derived material in your research? Don't hesitate to contact us for more information here: https://lnkd.in/eHH4bmZT #OncologyCRO #PreclinicalOncologyCRO #PancreaticCancer #PDX #PDO #PatientDerivedXenografts #PatientDerivedOrganoids #PDXOPlatform

CTC testing: Simple, fast, and powered by CELLSEARCH® Our CELLSEARCH LDT Lab Services provides clinicians with a minimally-invasive approach to monitor their patient's cancer journey by enumerating circulating tumor cells from a blood draw. With our proprietary CellSave and CellRescue Preservative Tubes -- which provide up to 120 hours of sample stability at room temperature -- blood samples can be shipped from anywhere in the U.S. to our CLIA-certified lab in Huntingdon Valley, PA. With results available approximatley 2 days from sample arrival to the lab, you can get the infomation you need faster than any other test on the market. Learn how you can order a test collection kit today. Visit https://lnkd.in/eNbEdSNK The performance, characteristics, safety, and effectiveness of the PD-L1 Biomarker with Enumeration, CMMC Enumeration, HER2 Biomarker with Enumeration, and CMC Enumeration lab-developed tests have not been cleared or approved by the FDA. The CELLSEARCH® Circulating Tumor Cell (CTC) test is FDA-cleared for detecting CTCs in cancer patients with metastatic breast, prostate*, or colorectal cancer. *Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. #HER2 #PD-L1 #multiplemyeloma #melanoma #LDT

CTC testing: Simple, fast, and powered by CELLSEARCH® Our CELLSEARCH LDT Lab Services provides clinicians with a minimally-invasive approach to monitor their patient's cancer journey by enumerating circulating tumor cells from a blood draw. With our proprietary CellSave and CellRescue Preservative Tubes -- which provide up to 120 hours of sample stability at room temperature -- blood samples can be shipped from anywhere in the U.S. to our CLIA-certified lab in Huntingdon Valley, PA. With results available approximatley 2 days from sample arrival to the lab, you can get the infomation you need faster than any other test on the market. Learn how you can order a test collection kit today. Visit https://lnkd.in/eNbEdSNK The performance, characteristics, safety, and effectiveness of the PD-L1 Biomarker with Enumeration, CMMC Enumeration, HER2 Biomarker with Enumeration, and CMC Enumeration lab-developed tests have not been cleared or approved by the FDA. The CELLSEARCH® Circulating Tumor Cell (CTC) test is FDA-cleared for detecting CTCs in cancer patients with metastatic breast, prostate*, or colorectal cancer. *Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. #HER2 #PD-L1 #multiplemyeloma #melanoma #LDT

Acute kidney injury affects 20-40% of patients after cardiac surgery, leading to increased morbidity and higher mortality rates. At KELI Therapeutics, we are developing cell and exosome therapies using potent mesenchymal stromal cells to enhance renal repair and reduce the incidence of chronic kidney disease. With promising data from our non-clinical studies and growing interest from the investment community, we see enormous potential to bring these treatments to patients globally. Our Chairman, Troels Jordansen, recently discussed the evolving investment landscape at Phacilitate Advanced Therapies Europe, emphasizing the progress of cell and gene research from the laboratory to clinical bedside applications. 🎥 https://lnkd.in/dSh_yyE2

𝗜𝗻 𝘃𝗶𝘁𝗿𝗼 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘃𝗼 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝗼𝗳 𝗼𝗰𝘂𝗹𝗮𝗿 𝘁𝗼𝗽𝗶𝗰𝗮𝗹𝗹𝘆 𝗮𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗲𝗿𝗲𝗱 𝗡𝗟𝗖 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝘂𝘃𝗲𝗮𝗹 𝗺𝗲𝗹𝗮𝗻𝗼𝗺𝗮 Uveal melanoma is one of the most common and aggressive intraocular malignancies, and, due to its great capability of metastasize, it constitutes the most incident intraocular tumor in adults. However, to date there is no effective treatment since achieving the inner ocular tissues still constitutes one of the greatest challenges in actual medicine, because of the complex structure and barriers. Uncoated and PEGylated nanostructured lipid carriers were developed to achieve physico-chemical properties (mean particle size, homogeneity, zeta potential, pH and osmolality) compatible for the ophthalmic administration of (S)-(–)-MRJF22, a new custom-synthetized prodrug for the potential treatment of uveal melanoma. Read more in the article ➡️ https://lnkd.in/ecme3f5j #excipients #Kolliphor by BASF Pharma Solutions #Softisan by IOI Oleo GmbH

MediciNova, Inc.’s Patent Application for Ibudilast (MN-166) Gains Notice of Allowance to Prevent Metastasis of Multiple Solid Cancer #medicinova #ibudilast #mn166 #solidtumor #regulatory #uspto #patent #noticeofallowance #pancreaticcancer #lungcancer #breastcancer #colorectalcancer #ovariancancer #melanoma #smallmolecule #metastasis #radiotherapy #photodynamictherapy #epigenetictherapy #phosphodiesterase4 #inflammatorycytokines #neurodegenerativediseases #glioblastoma #covid #cipn #ards

The maytansine scaffold has been used to generate #ADCs which are at different stages of clinical trials, including an ADC that has been approved by the FDA. In our recent poster with Regeneron, we share how our close collaboration enabled us to successfully deliver a new series of maytansine-based cytotoxic payloads for ADCs that displayed in vivo activity in the Ovcar3 tumor model. Access the poster here: https://lnkd.in/gWRT25Ef Abzena poster authors included Francisco Velazquez. #bioconjugates #CDMO #CRO #antibodies

The Celloger ® Pro is a game-changer for cancer research. It allows capture high-resolution images and videos of multiple cell samples in both brightfield and fluorescence microscopy, without disturbing their growth conditions. You can also set up a schedule for time-lapse imaging and remotely access the data from my PC. The Celloger ® Pro's user-friendly interface and intuitive tools make image acquisition and analysis a seamless experience. With the Celloger ® Pro, you can explore various aspects of cancer biology, such as cell proliferation, migration, invasion, apoptosis, angiogenesis, metastasis, drug response, and more. I can also visualize and track the dynamics of intracellular events and mechanisms, such as gene expression, protein localization, signal transduction, and cell cycle. The Celloger ® Pro provides rich and reliable data that can help me advance my research and discover new insights.If you are interested in learning more about the Celloger ® Pro and how it can benefit your cancer research, I highly recommend checking out the following link https://lnkd.in/e-fVwji7 #CancerResearch #CellogerPro #BreakthroughTechnology